SOUTH SAN FRANCISCO, Calif. , Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy , D.Phil ., chief executive officer and chairman, will participate in a fireside chat at

- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. - - Phase 1 study of CX-2051 (EpCAM PROBODY® ADC) in advanced colorectal cancer (CRC) is currently in the fifth dose escalation cohort.

SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report third quarter financial results on Thursday, November 7, 2024 , after the

SOUTH SAN FRANCISCO, Calif. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study ( NCT06462794 )

SOUTH SAN FRANCISCO, Calif. , Sept. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. H.C.

- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - - Phase 1 clinical study of CX-2051, an EpCAM targeting PROBODY ® ADC, is ongoing. Study is currently enrolling third cohort with

SOUTH SAN FRANCISCO, Calif. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial results on Thursday, August 8, 2024 , after the

SOUTH SAN FRANCISCO, Calif. , June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy , D.Phil ., chief executive officer and chairman, will participate in a

SOUTH SAN FRANCISCO, Calif. , June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024 .

SOUTH SAN FRANCISCO, Calif. , May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy , D.Phil ., chief executive officer and chairman, will present at the Jefferies